AZAndrey V. Zavialov

Andrey V. Zavialov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Andrey V. Zavialov has a total of 158 co-authors. Here are the top co-authors by number of shared publications:

  • Måns Ehrenberg

    Department of Cell and Molecular Biology, Biomedical Center, S-75124 Uppsala, Sweden

    15 shared publications
  • Joachim Frank

    6 shared publications
  • Jayati Sengupta

    Wadsworth Center, State University of New York at Albany, Empire State Plaza, Albany, New York 12201

    5 shared publications
  • Mikel Valle

    Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 801A, 48160 Derio, Spain

    5 shared publications
  • Chengxiang Wu

    Tulane National Primate Research Center, Tulane University, Covington, LA, United States

    4 shared publications
  • Qing Zhou

    Life Sciences Institute, Zhejiang University, Hangzhou, China

    4 shared publications

Latest Publications

  • Open Access

    A rapid antigen test to detect adenosine deaminase 2 (ADA2) in biological fluids and its application in clinical diagnostics

    by Weiping Yang, Qing Zhou, Jose M. Porcel, Jun Wang, Chengxiang Wu, Andrey V. Zavialov

    Introduction: Saliva biomarkers provide a convenient and noninvasive method for diagnosing immune and genetic disorders. One such biomarker is adenosine deaminase 2 (ADA2), an enzyme that converts adenosine into inosine and is elevated in cancer and immune diseases. Currently, ADA2 activity can be used to diagnose pleural tuberculosis. Recently, we developed an ELISA assay that detects ADA2 in saliva. This test has been successfully employed to diagnose adenosine deaminase 2 deficiency (DADA2) and potentially to identify individuals with head and neck cancer. DADA2 is a rare genetic disease that can lead to systemic vasculitis, early onset stroke, bone marrow failure, and/or immunodeficiency. A rapid, simple, and affordable point-of-care (POC) test would significantly aid in diagnosing DADA2 and facilitate appropriate treatment.Methods: In this study, we created a novel colloidal gold-based immunochromatographic strip (ICS) containing polyclonal antigen-purified anti-ADA2 antibodies. The ADA2 rapid antigen test (RAT) was calibrated precisely to detect ADA2 in the saliva of healthy individuals, while those with ADA2 deficiency received negative results.Results: The test successfully confirmed DADA2 in nine patients with different pathogenic mutations in ADA2, while 58 of 59 healthy donors tested positive for ADA2. Discussion: The ADA2 rapid antigen test reliably screens patients with autoimmune disorders, accurately diagnosing DADA2. This test can also be used to diagnose pleural tuberculosis or other diseases with significantly elevated ADA2 levels.

  • Open Access

    Developing and validating anti-ADA2 single-chain antibodies coupled to alkaline phosphatase for diagnosing pleural tuberculosis

    by Maksym Skaldin, José M Porcel, Urpo Lamminmäki, Silvia Bielsa, Andrey V Zavialov

    Introduction: Adenosine deaminases ADA1 and ADA2 reduce adenosine concentrations, which regulate cellular immune responses to activation signals. It has been shown that ADA2 activity increases in the pleural fluid of patients with tuberculosis (TB).Methods: We engineered recombinant scFv-AP antibodies using phage display technology to select high-affinity binders against ADA2. These were incorporated into a sandwich ELISA, allowing for the precise measurement of ADA2 levels in pleural fluid.Results: The assay was tested on pleural samples from 41 patients with TB and 47 with non-TB effusions, including those with malignancies and parapneumonic effusions. Results showed that ADA2 concentrations were significantly higher in patients with TB than in other groups, and the ADA2-based assay exhibited improved diagnostic specificity (91%) compared with total ADA testing (76%). A cutoff of 300 ng/mL for ADA2 yielded a sensitivity of 98% and a negative likelihood ratio of 0.03, effectively ruling out TB when the result was negative.Discussion: The new ADA2 assay offers a simple, reliable, and more specific alternative for diagnosing pleural TB, with potential applications in other ADA2-related disorders.


  • Intracellular concentration of ADA2 is a marker for monocyte differentiation and activation

    by Liang Dong, Bingtai Lu, Wenwen Luo, Xiaoqiong Gu, Chengxiang Wu, Luca Trotta, Mikko Seppanen, Yuxia Zhang, Andrey V. Zavialov

    Adenosine, a critical molecule regulating cellular function both inside and outside cells, is controlled by two human adenosine deaminases: ADA1 and ADA2. While ADA1 primarily resides in the cytoplasm, ADA2 can be transported to lysosomes within cells or secreted outside the cell. Patients with ADA2 deficiency (DADA2) often suffer from systemic vasculitis due to elevated levels of TNF-α in their blood. Monocytes from DADA2 patients exhibit excessive TNF-α secretion and differentiate into pro-inflammatory M1-type macrophages. Our findings demonstrate that ADA2 localizes to endolysosomes within macrophages, and its intracellular concentration decreases in cells secreting TNF-α. This suggests that ADA2 may function as a lysosomal adenosine deaminase, regulating TNF-α expression by the cells. Interestingly, pneumonia patients exhibit higher ADA2 concentrations in their bronchoalveolar lavage (BAL), correlating with elevated pro-inflammatory cytokine levels. Conversely, cord blood has low ADA2 levels, creating a more immunosuppressive environment. Additionally, secreted ADA2 can bind to apoptotic cells, activating immune cells by reducing extracellular adenosine levels. These findings imply that ADA2 release from monocytes during inflammation, triggered by growth factors, may be crucial for cell activation. Targeting intracellular and extracellular ADA2 activities could pave the way for novel therapies in inflammatory and autoimmune disorders.


  • Adenosine deaminase 2 regulates the activation of the toll-like receptor 9 in response to nucleic acids

    by Liang Dong, Wenwen Luo, Skaldin Maksym, Simon C. Robson, Andrey V. Zavialov

    Human cells contain two types of adenosine deaminases (ADA) each with unique properties: ADA1, which is present in all cells where it modulates intracellular functions and extracellular signaling, and ADA2, which is secreted by immune cells. The exact intracellular functions of ADA2 remain undetermined and less defined than those of ADA1. ADA2 has distinct characteristics, such as low adenosine affinity, heparin-binding ability, and putative lysosomal entry. Here, we confirm that ADA2 is a lysosomal protein that binds toll-like receptor 9 (TLR9) agonists, specifically CpG oligodeoxynucleotides (CpG ODNs). We show that interferon-alpha (IFN-α) is secreted in response to TLR9 activation by CpG ODNs and natural DNA and markedly increases when ADA2 expression is downregulated in plasmacytoid dendritic cells (pDCs). Additionally, the pretreatment of pDCs with RNA further stimulates IFN-α secretion by pDCs after activation with CpG ODNs. Our findings indicate that ADA2 regulates TLR9 responses to DNA in activated pDCs. In conclusion, decreasing ADA2 expression or blocking it with specific oligonucleotides can enhance IFN-α secretion from pDCs, improving immune responses against intracellular infections and cancer.


  • Open Access

    ELISA based assays to measure adenosine deaminases concentration in serum and saliva for the diagnosis of ADA2 deficiency and cancer

    by Wenwen Luo, Liang Dong, Fenghong Chen, Wenbin Lei, Liya He, Qing Zhou, Thierry Lamy, Andrey V. Zavialov

    Adenosine deaminases (ADAs) are enzymes of purine metabolism converting adenosine to inosine. There are two types of ADAs in humans ADA1 and ADA2. While both ADA1 and ADA2 share the same substrate, they differ in expression, cellular localization, and catalytic properties. The genetic deficiency of ADA1 results in severe combined immunodeficiency (SCID), while lack in ADA2 (DADA2) results in multiple phenotypes ranging from systemic inflammation to vascular pathology. Clinical studies have shown that the levels of ADAs in biological fluids are altered in pathophysiological conditions, suggesting that ADA activity could be a convenient marker for the diagnosis of immune diseases and cancer. Here, we describe sensitive and straightforward ELISA assays to measure ADA1 and ADA2 concentrations in biological fluids. Analysis of the serum and saliva samples from the healthy controls and DADA2 patients revealed that ADA2 enzyme concentration is significantly lower in patients than in healthy controls. In contrast, the concentration of ADA2 increases in the serum of patients with large granular leukocyte leukemia (LGLL) and patients’ saliva with head and neck cancer. Thus, this simple, non-invasive method allows for distinguishing healthy controls from the affected patient. It can be implemented in screening and diagnosis of DADA2 and follow up the treatment of LGLL and several types of head and neck cancer.


  • ADA2 deficiency: Clonal lymphoproliferation in a subset of patients

    by Luca Trotta, Timi Martelius, Timo Siitonen, Timo Hautala, Sari Hämäläinen, Hanna Juntti, Mervi Taskinen, Mette Ilander, Emma Irene Andersson, Andrey Zavialov, et al.


  • Human adenosine deaminases ADA1 and ADA2 bind to different subsets of immune cells

    by Yuliia Kaljas, Chengqian Liu, Maksym Skaldin, Chengxiang Wu, Qing Zhou, Yuanan Lu, Ivona Aksentijevich, Andrey V. Zavialov

    At sites of inflammation and tumor growth, the local concentration of extracellular adenosine rapidly increases and plays a role in controlling the immune responses of nearby cells. Adenosine deaminases ADA1 and ADA2 (ADAs) decrease the level of adenosine by converting it to inosine, which serves as a negative feedback mechanism. Mutations in the genes encoding ADAs lead to impaired immune function, which suggests a crucial role for ADAs in immune system regulation. It is not clear why humans and other mammals possess two enzymes with adenosine deaminase activity. Here, we found that ADA2 binds to neutrophils, monocytes, NK cells and B cells that do not express CD26, a receptor for ADA1. Moreover, the analysis of CD4+ T-cell subset revealed that ADA2 specifically binds to regulatory T cells expressing CD39 and lacking the receptor for ADA1. Also, it was found that ADA1 binds to CD16− monocytes, while CD16+ monocytes preferably bind ADA2. A study of the blood samples from ADA2-deficient patients showed a dramatic reduction in the number of lymphocyte subsets and an increased concentration of TNF-α in plasma. Our results suggest the existence of a new mechanism, where the activation and survival of immune cells is regulated through the activities of ADA2 or ADA1 anchored to the cell surface.


  • Open Access

    Application of ADA1 as a new marker enzyme in sandwich ELISA to study the effect of adenosine on activated monocytes

    by Chengqian Liu, Maksym Skaldin, Chengxiang Wu, Yuanan Lu, Andrey V. Zavialov

    Enzyme-linked immunosorbent assay (ELISA) is a valuable technique to detect antigens in biological fluids. Horse radish peroxidase (HRP) is one of the most common enzymes used for signal amplification in ELISA. Despite new advances in technology, such as a large-scale production of recombinant enzymes and availability of new detection systems, limited research is devoted to finding alternative enzymes and their substrates to amplify the ELISA signals. Here, HRP-avidin was substituted with the human adenosine deaminase (hADA1)-streptavidin complex and adenosine as a detection system in commercial ELISA kits. The hADA1 ELISA was successfully used to demonstrate that adenosine, bound to A1 and A3 adenosine receptors, increases cytokine secretion by LPS activated monocytes. We show that hADA1-based ELISA has the same sensitivity, and also provides identical results, as HRP ELISA. In addition, the sensitivity of hADA1-based ELISA could be easily adjusted by changing the adenosine concentration and the incubation time. Therefore, hADA1 could be used as a detection enzyme with any commercial ELISA kit with a wide range of concentration of antigens.


  • Open Access

    Dermatologic Features of ADA2 Deficiency in Cutaneous Polyarteritis Nodosa

    by Tania M. Gonzalez Santiago, Andrey Zavialov, Janna Saarela, Mikko Seppanen, Ann M. Reed, Roshini S. Abraham, Lawrence E. Gibson

    Importance Mutations in theCERC1gene associated with deficiency in the ADA2 protein (DADA2) have been implicated in the pathogenesis of cutaneous polyarteritis nodosa (cPAN) and early-onset vasculopathy. DADA2 is not only limited to cPAN and vasculopathy but also includes immunodeficiency that affects several cellular compartments, including B cells; however, some patients appear to have a more indolent, skin-limited disease. Observations In this report, we describe 2 white siblings (female and male) with a history of cPAN with DADA2 as a result of novel compound heterozygous mutations inherited in trans in theCECR1gene (c.37_39del [p.K13del] and c.984C>A [p.N328K]). The onset of disease was earlier in the female sibling than the male sibling although both were diagnosed as having cPAN in early childhood. The disease is associated with a more significant immunodeficiency and other systemic symptoms in the female than the male sibling. Conclusions and Relevance These findings suggest a genetic cause of cPAN in some patients. Therefore, DADA2 should be considered in patients with cPAN, specifically in those whose conditions are diagnosed at an early age, regardless of their ethnicity, presence or absence of systemic symptoms, or a family history of the disease.


  • Top Cited Papers

    Early-Onset Stroke and Vasculopathy Associated with Mutations in ADA2

    by Qing Zhou, Dan Yang, Amanda K. Ombrello, Andrey V. Zavialov, Camilo Toro, Deborah L. Stone, Jae Jin Chae, Sergio D. Rosenzweig, Kevin Bishop, Karyl S. Barron, et al.

    We observed a syndrome of intermittent fevers, early-onset lacunar strokes and other neurovascular manifestations, livedoid rash, hepatosplenomegaly, and systemic vasculopathy in three unrelated patients. We suspected a genetic cause because the disorder presented in early childhood. We performed whole-exome sequencing in the initial three patients and their unaffected parents and candidate-gene sequencing in three patients with a similar phenotype, as well as two young siblings with polyarteritis nodosa and one patient with small-vessel vasculitis. Enzyme assays, immunoblotting, immunohistochemical testing, flow cytometry, and cytokine profiling were performed on samples from the patients. To study protein function, we used morpholino-mediated knockdowns in zebrafish and short hairpin RNA knockdowns in U937 cells cultured with human dermal endothelial cells. All nine patients carried recessively inherited mutations in CECR1 (cat eye syndrome chromosome region, candidate 1), encoding adenosine deaminase 2 (ADA2), that were predicted to be deleterious; these mutations were rare or absent in healthy controls. Six patients were compound heterozygous for eight CECR1 mutations, whereas the three patients with polyarteritis nodosa or small-vessel vasculitis were homozygous for the p.Gly47Arg mutation. Patients had a marked reduction in the levels of ADA2 and ADA2-specific enzyme activity in the blood. Skin, liver, and brain biopsies revealed vasculopathic changes characterized by compromised endothelial integrity, endothelial cellular activation, and inflammation. Knockdown of a zebrafish ADA2 homologue caused intracranial hemorrhages and neutropenia — phenotypes that were prevented by coinjection with nonmutated (but not with mutated) human CECR1. Monocytes from patients induced damage in cocultured endothelial-cell layers. Loss-of-function mutations in CECR1 were associated with a spectrum of vascular and inflammatory phenotypes, ranging from early-onset recurrent stroke to systemic vasculopathy or vasculitis. (Funded by the National Institutes of Health Intramural Research Programs and others.)